ARTICLE | Clinical News
EPI-HNE-4: Began Phase IIa trial
February 20, 2001 8:00 AM UTC
Dyax Corp. (DYAX), Cambridge, Mass. Product: EPI-HNE-4 Business: Antibodies Therapeutic category: Enzyme inhibitor Target: Neutrophil elastase Description: Polypeptide inhibitor of neutrophil elastas...